EP0556285A4 - Synergistic therapy with combinations of anti-tumor antibodies and biologically active agents - Google Patents

Synergistic therapy with combinations of anti-tumor antibodies and biologically active agents

Info

Publication number
EP0556285A4
EP0556285A4 EP19920900028 EP92900028A EP0556285A4 EP 0556285 A4 EP0556285 A4 EP 0556285A4 EP 19920900028 EP19920900028 EP 19920900028 EP 92900028 A EP92900028 A EP 92900028A EP 0556285 A4 EP0556285 A4 EP 0556285A4
Authority
EP
European Patent Office
Prior art keywords
combinations
biologically active
active agents
tumor antibodies
synergistic therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19920900028
Other versions
EP0556285A1 (en
Inventor
Ingegerd Hellstroem
Karl Erik Hellstroem
George Schreiber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of EP0556285A1 publication Critical patent/EP0556285A1/en
Publication of EP0556285A4 publication Critical patent/EP0556285A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
EP19920900028 1990-11-05 1991-10-18 Synergistic therapy with combinations of anti-tumor antibodies and biologically active agents Withdrawn EP0556285A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60955790A 1990-11-05 1990-11-05
US609557 1990-11-05

Publications (2)

Publication Number Publication Date
EP0556285A1 EP0556285A1 (en) 1993-08-25
EP0556285A4 true EP0556285A4 (en) 1993-10-27

Family

ID=24441285

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19920900028 Withdrawn EP0556285A4 (en) 1990-11-05 1991-10-18 Synergistic therapy with combinations of anti-tumor antibodies and biologically active agents

Country Status (4)

Country Link
EP (1) EP0556285A4 (en)
JP (1) JPH06501705A (en)
CA (1) CA2095141A1 (en)
WO (1) WO1992007466A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5980896A (en) * 1989-06-30 1999-11-09 Bristol-Myers Squibb Company Antibodies reactive with human carcinomas
US7744877B2 (en) 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
RO118524B1 (en) 1992-11-13 2003-06-30 Idec Pharmaceuticals Corp San Method for treating a disorder related to cells b
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5792456A (en) * 1994-08-04 1998-08-11 Bristol-Myers Squibb Company Mutant BR96 antibodies reactive with human carcinomas
AU4134497A (en) * 1996-09-03 1998-03-26 Chugai Seiyaku Kabushiki Kaisha Anti-integrin alpha3 antibody complexes
DE69939939D1 (en) 1998-08-11 2009-01-02 Idec Pharma Corp COMBINATION THERAPIES AGAINST B-CELL LYMPHOMA CONTAINS THE ADMINISTRATION OF ANTI-CD20 ANTIBODIES
EP1949912A3 (en) 1998-11-09 2008-08-13 Biogen Idec, Inc. Treatment of chronic lymphcytic leukemia (CLL) using chimeric anti-CD20 antibody
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
EP1918305A1 (en) 1999-08-11 2008-05-07 Biogen Idec Inc. New clinical parameters for determining hematologic toxicity prior to radioimmunotherapy
US6451284B1 (en) 1999-08-11 2002-09-17 Idec Pharmaceuticals Corporation Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
US8287864B2 (en) 2002-02-14 2012-10-16 Immunomedics, Inc. Structural variants of antibodies for improved therapeutic characteristics
CN100522999C (en) 2002-02-14 2009-08-05 免疫医疗公司 Anti-CD20 antibodies and fusion proteins thereof and methods of use
RS57466B1 (en) 2003-11-05 2018-09-28 Roche Glycart Ag Antigen binding molecules with increased fc receptor binding affinity and effector function
US7740847B2 (en) 2004-08-04 2010-06-22 Applied Molecular Evolution, Inc. Variant Fc regions
US8475794B2 (en) 2005-04-06 2013-07-02 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
EA201100228A1 (en) 2008-07-21 2011-08-30 Иммьюномедикс, Инк. STRUCTURAL VARIANTS OF ANTIBODIES TO IMPROVE THE THERAPEUTIC CHARACTERISTICS
CN105168204A (en) * 2015-09-06 2015-12-23 江志鑫 Pharmaceutical composition containing mitomycin and capable of resisting colon cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0359282B1 (en) * 1988-09-15 1995-05-24 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic compositions containing same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0359282B1 (en) * 1988-09-15 1995-05-24 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic compositions containing same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9207466A1 *

Also Published As

Publication number Publication date
WO1992007466A1 (en) 1992-05-14
JPH06501705A (en) 1994-02-24
CA2095141A1 (en) 1992-05-06
EP0556285A1 (en) 1993-08-25

Similar Documents

Publication Publication Date Title
EP0556285A4 (en) Synergistic therapy with combinations of anti-tumor antibodies and biologically active agents
ZA913879B (en) Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy
GR1002240B (en) Agents for the prophgylaxis and therapy of retroviral infections
HK1094148A1 (en) Synergistic therapeutic compositions and methods
GB8914598D0 (en) Niacin-containing composition and its therapeutic use
GB8907148D0 (en) Biologically active proteins
HU9201254D0 (en) Rapamicine-carbamates and medical preparations containing them as active agents
PT78049A (en) Biologically active ketone derivative preparation and use
GB9007730D0 (en) Therapeutic compound and composition
AU9011891A (en) Synergistic therapy with combinations of anti-tumor antibodies and biologically active agents
GB9307948D0 (en) Biologically active ureido derivatives useful in the treatment of lentivirus-induced disease
EP0470474A3 (en) Implantable devices and materials
ZA893261B (en) Synergistic combinations and their use as therapeutic agents
NO931636D0 (en) SYNERGISTIC THERAPY WITH COMBINATIONS OF ANTI-TUMOR ANTIBODIES AND BIOLOGICALLY ACTIVE COMPOUNDS
GB9111885D0 (en) Nerve growth factor for use in the prevention and treatment of viral infections
GB2245475B (en) Improvements in the treatment of animal feeds
GB9013872D0 (en) Use of protein a and polypeptide components thereof in the treatment of tumours
IE901329L (en) Composition and treatment with biologically active peptides¹and antibiotic
PL277241A1 (en) Agent stimulating growth of ruminants
GB9119202D0 (en) Biologically and therapeutically active agents
AR242073A1 (en) Composition and treatment with biologically active peptides and certain anions
GB9207273D0 (en) Biologically and therapeutically active agents
GB9215546D0 (en) Biologically and therapeutically active agents
ZA902525B (en) Composition and treatment with biologically active peptides and antibiotic
IE893379L (en) Composition and treatment with biologically active peptides¹and certain anions

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930603

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19930909

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17Q First examination report despatched

Effective date: 19950823

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19960103